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Progressive osseous heteroplasia (POH; OMIM 166350) is a rare autosomal-dominant
genetic disorder in which extra-skeletal bone forms within skin and muscle tissue. POH
is one of the clinical manifestations of an inactivating mutation in the GNAS gene. GNAS
gene alterations are difficult matter to address, as GNAS alleles show genetic imprinting
and produce several transcript products, and the same mutation may lead to strikingly
different phenotypes. Also, most of the publications concerning POH patients are either
clinical depictions of a case (or a case series), descriptions of their genetic background,
or a tentative correlation of both clinical and molecular findings. Treatment for POH is
rarely addressed, and POH still lacks therapeutic options. We describe a unique case
of POH in two monochorionic twins, who presented an almost asymptomatic vs. the
severe clinical course, despite sharing the same mutation and genetic background. We
also report the results of the therapeutic interventions currently available for heterotopic
ossification in the patient with the severe course. This article not only critically supports
the assumption that the POH course is strongly influenced by factors beyond genetic
background but also remarks the lack of options for patients suffering an orphan disease,
even after testing drugs with promising in vitro results.
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INTRODUCTION
Progressive osseous heteroplasia (POH; OMIM 166350) is a rare autosomal-dominant genetic
disorder in which extra-skeletal bone forms within skin and muscle tissue (1). Most cases of POH
are caused by heterozygous inactivating mutations of the GNAS gene on the paternal allele (2, 3).
GNAS encodes the alpha subunit of the G-stimulatory protein of adenylyl cyclase (Gsα). The scarce
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cases, the variability in clinical presentation, and the
unpredictable evolution hamper the study of the disease,
which in many cases leads to deformities, ankylosis, loss of
functionality, and even amputation (4, 5).
We describe for the first time the case of two monochorionic
twins suffering from POH, with almost asymptomatic vs.
severe clinical course of the disease. Our aim is 2-fold: (i)
to bring the focus on the different clinical evolution despite
patients having an identical genetic background and (ii) to
review the treatment options for severe POH and communicate
our experience.
CASE PRESENTATION
Two 4-year-old monochorionic–diamniotic twins with a
diagnosis of POH were referred to our practice for evaluation
and follow-up. Clinical evolution and analytical findings of both
siblings can be seen in Table 1 and Supplementary Figure 1.
Their condition as monozygotic twins was tested by carrying
out whole-genome single nucleotide polymorphism (SNP)
genotyping (including 715.195 SNPs) of blood and saliva
samples obtained from both sisters and a sample of bone
plate from the severe affected twin. The statistical analyses
confirmed that the twins are genetically identical and also the
absence of detectable mosaicism in the tissue samples analyzed
(Supplementary Figure 2).
Due to the rapid progression of disease and risk of
permanent disability in the first twin, a review of the therapeutic
options recorded in the literature was carried out and a
subsequent treatment protocol was devised. The order of
the therapeutic choices was established weighing the existing
evidence for treatment of ectopic ossification processes against
the severity of possible side effects and the disruption caused
in normal life activities (Figure 1; Supplementary Figure 3).
As the condition of the second twin remained stationary,
interventions were only applied to the first sibling. All
treatments included were approved as compassionate drug
use by all the departments involved (Pediatrics, Neonatology,
Endocrinology, Gastroenterology, Immunology and Infectious
Diseases, Neurology, Pediatric Surgery, Dermatology, Chronic
Patients Unit, Traumatology, Rehabilitation and Physiotherapy,
Pharmacy, and Laboratory).
We chose to assess procollagen type I N-terminal peptide
(PINP) and beta-cross lap levels during protocol follow-up. For
that purpose, blood samples were drawn before starting a new
treatment, fortnightly while maintaining that therapy and after
drug withdrawal. Flare-ups were defined as periods of asthenia
and muscular complaint that extended for five or more days,
accompanied by evidence of progression of already existent
lesions or formation of new ones.
Abbreviations: FOP, Fibrodisplasia Ossificans Progressiva; Gsα, α-subunit of
the G-protein; Hh, Hedgehog; HO, Heterotopic ossification; IGF-1, Insulin-
like Growth Factor-1; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs;
PINP, procollagen type 1 N-terminal propeptide; POH- Progressive Osseous
Heteroplasia; rhIGF-1, Mecasermin (recombinant human Insulin-like Growth
Factor-1); SCI, Spinal Cord Injury.
A chronogram depicting the drugs administered to Patient
1 and their effects on the chosen serum markers can be found
in Figure 1. Table 2 resumes dosing, adverse events found, and
causes for discontinuation of the selected therapies.
Our novel IGF-1 therapeutic approach was based on its
role as an equipoise of bone metabolism (Figure 1) (6–
8), it acts as a powerful regulator of osteoclastogenesis
and the reabsorptive function of osteoclasts (19). Moreover,
immunological experiments in animals genetically modified
to nullify the expression of the gene for IGF-1 showed
excessive and uncontrolled growth of bone tissue due to
osteoclastic inhibition (20). After administration of IGF-1 to
our patient, serum levels of substances thought to upregulate
osteoclasts (Beta-crosslaps) rose by 10% (1.71 pre-intervention
to 1.87 ng/ml post-intervention), whereas PINP (promoting
osteoblasts) concentrations rose by 30% (from 853.6 to
1177 ng/ml). This effect is similar to the results obtained from
IGF-1 administration in both healthy subjects and patients with
other pathologies (21, 22).
In our case, decreased IGF-1 values seem to be the result of the
underlying altered molecular pathways found in POH and not a
cause or a key player. It may also be possible that subcutaneous
administration of IGF-1 has no effect on bone formation or
that higher doses are required to elicit a response. Our results
may also be influenced by the fact that IGF-1 acts in the latter
stages of bone maturation (22). Low levels of IGF-1 can also
translate to an impaired GH secretion (23). Whenever tested,
serum GH concentrations were found to be in adequate levels
for its age in our patient, and the same happened to IGFBP-3
concentrations (a protein binding IGF-1). Although maternally
derived GNAS mutations may lead to GHRH resistance and
therefore low circulating levels of GH, most cases of POH are
caused by heterozygous inactivating mutations of the GNAS gene
on the paternal allele. What is more, alterations in paternal and
maternal alleles drive to strikingly distinct phenotypes—slim in
paternally—inherited mutations (as happened to our subject),
and obesity in GNAS disturbances of maternal origin (24). We
did not test the patient’s response to provocative test for GH
secretion; reproducibility remains an issue with these tests, and
at the time of the initial assessment, the severely affected girl did
not comply with the consensus criteria proposed for them (23).
Our clinical and analytical work-up also suggested the absence
of a concomitant hypopituitarism. Lastly, lower levels of IGF-
1 can also be found in states of poor nutrition (23), and the
continued bone formation of POHmay have likely had an impact
on metabolic expenses.
It has been suggested that retinoic acid increases the
production of Gsα protein from the normal allele (10). Use of
selective retinoic acid receptor agonist for inhibition of ectopic
bone formation has been reported by Shimono et al. (11, 12).
Isotretinoin, in fact, has been used for patients with fibrodisplasia
ossificans progressiva (FOP) (13). However, retinoic acid
receptor Y agonists inhibit endochondral ossification, which may
be present in up to 50% patients with POH, but the typical feature
of POH is the intramembranous ossification. Future studies with
another retinoic (palovarotene) in FOP may shed more light on
this matter (25, 26), but both courses of topical and systemic
retinoids failed in stopping disease progression in our case.
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TABLE 1 | Clinical history of both patients.
Variables Patient 1 Patient 2
Birth Pre-term—31 weeks of gestational age
No deformities at birth
Family history Mother: vitiligo, hypothyroidism, migraine
Father: bilateral calcifications after tearing of both Achilles’ tendons
No Intermarriage between parental families
Initial symptoms 10 weeks of extrauterine life
Hard subcutaneous papules in both tights Three minimal subcutaneous spikes that
remained stationary to date
Genetic characterization Heterozygous missense mutation in exon 7 consisting of a 4 bp deletion (GACT; GNAS n565-568;
20q13), de novo mutation
Progression of the disease Progressed rapidly: Ankylosis of the left leg and
calcification of deep tissues in the right leg, her back and
the adipose tissue of both iliac fossae. At the time of their
first visit to our practice, the illness started to impair joints
of the right lower limb (the one still allowing
walking—Supplementary Figure 1) Ibuprofen (8
mg/kg/dose) was required to mitigate pain
Remained largely unaffected by the disease.
No new calcifications.
Biochemical and hematological parameters
Insulin Growth Factor-1 (ng/mL). 39.7 56.2
NR: 49-327 ng/mL
Growth hormone (ng/mL). NR: <5.00 1.28 1.07
Bone Alkaline Phosphatase (BAP) levels (mcg/L). NR:
41-134
236 122
Amino-terminal propeptide of type I collagen (PINP)
(ng/mL). NR: 277-824
853.6 666.7
Beta carboxy-terminal telopeptide of type 1 collagen
(beta-crosslaps) (ng/mL). NR: 0.57-1.84
1.71 1.29
Serum calcium (mg/dL). NR: 9.2-10.3 10.2 10.3
25hydroxy-vitamin D (ng/mL) 25 21
NR: 12-54
Ionic phosphate (mg/dL). NR: 3.5-5.5 3.9 5
Osteocalcin (ng/mL) 47.2 25.4
NR: 2.8-41
Parathyroid hormone (pg/mL) 35 36
NR: 9-59





RF* (NR 35-60UI/dL) <35 <35
A-Sm* Negative Negative
The girls are monochorionic-diamniotic twins and therefore share the same genetic background.
ANA*, anti-nuclear antibodies; AMA*, anti-mitochondrial antibodies; ANCA*, anti-neutrophil cytoplasmic antibodies; RF*, rheumatoid factor; A-Sm*, anti-Smith antibody; NR,
normal range.
Another treatment used for ectopic bone formation is
thiazolidinediones, a class of antidiabetic drugs, which activate
the peroxisome proliferator-activated receptor–γ (PPAR-γ)
that, in bone, controls cell differentiation of mesenchymal
and hematopoietic lineages. Thiazolidinedione use has been
linked to increased bone resorption and decrease of bone
formation (27). Thus, Gatti et al. (28) used rosiglitazone (a
thiazolidinedione) during a 14-month period in a 48-year-old
woman suffering from FOP, allowing a progressive tapering
of the corticosteroid therapy the patient was on, and a clear
improvement of joint mobility and skin softness. However,
in our case, rosiglitazone was not considered due to its
unknown security profile for children as young as our
patient. Moreover, so far, results of an open-label study
designed for further testing the effects of rosiglitazone in
FOP remain undisclosed (29). It is noteworthy that this
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FIGURE 1 | Chronogram depicting treatments received and evolution of the disease in the first twin. The graphic starts with levels of PINP and beta-crosslaps
obtained in the 4 weeks prior to the beginning of the first intervention (administration of mecasermin or rhIGF-1, which corresponds to the beginning of month II).
Levels of PINP and beta-crosslaps have been moving around the same values in the previous 12 months, where we began to measure them. After the failure of the
corticosteroid therapy, parents and the medical team agreed to stop the fortnightly blood draws and to follow evolution based on clinical parameters, to reduce
intervention and hospital visits, thus minimizing the interference with daily activities. PINP—amino-terminal propeptide of type I collagen.
therapeutic approach is currently considered still occasionally
[e.g., see the last consensus for medical management of
FOP (26)].
Biphosphonates, such as Etidronate, block the mineralization
of the bone matrix. In our patient, disease progression (measured
by the formation of new lesions and progression of older
ones) was not modified by administration of intravenous
pamidronate, despite a decrease in markers of bone remodeling.
Larger courses of Pamidronate are associated with “freezing”
of bone metabolism, decreasing bone formation, as well as
resorption (14). But for treating active flares of ectopic bone
formation, evidence of such “freezing” is feeble (16, 30,
31). Etidronate has also been used for the prevention of
heterotopic ossification (HO), and it seemed to retard osteoid
calcification, as ossification continued when bisphosphonate was
discontinued (32), because matrix formation remains unaffected
(17). Despite some authors reporting pamidronate to ameliorate
FOP symptoms in up to three quarters of their patients,
current FOP management guidelines inform of the limited
long-term utility of this approach, as repeated infusions may
lead to fractures in the normal bone and biphosphonates seem
to offer no protective effects against future flare-ups (26).
In any case, we were not able to provide further doses of
pamidronate and test the effects of a greater cumulative dosage,
as pamidronate infusion was accompanied of numerous adverse
events mimicking symptoms of active disease (asthenia, myalgia,
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TABLE 2 | Drugs used in Patient 1.
Drug Dose Mechanism AL Adverse events Cause of discontinuation References
Mecasermin
(rhIGF-1)
0.04 mg/day rhIGF-I 15 No Worsened serum markers;
same clinical
(6–8)




Gsα expression at a
transcriptional level





Oral acitretin 10 mg/day 90 No Coalescence of bony spikes
of the back and progression
of the plate over the left
scapula, as well as




Pamidronate 2.5 mg/kg Bisphosphonate: Slows




3 Worsened myalgia and














bone formation returned to
previous levels, and
absence of clinical








improvement in the disease
progression, despite
reuction of markers of bone





NSAIDs 180 Currently on indomethacin. (17, 18)
AL, administration length (days); b.i.d, bis in die (twice daily); q.d, quaque die (once a day).
pain when standing, early fatigability, etc.) lasting more than
a week.
Hedgehog (Hh) signaling is required in both endochondral
and intramembranous ossification (33). In normal soft tissues,
Gsα inhibits Hh signaling and restricts spatially the bone
formation to the normal skeleton. Hh upregulation is both
necessary and sufficient to induce HO (34). At the same time,
the loss of Gsα inhibition on Hh signaling can lead to the
development of medulloblastoma (35). Itraconazole is an orally
administered antifungal that acts as a potent suppressor of the
Hh signaling pathway. The same dosage used for treating fungal
infections inhibits the growth of medulloblastoma in mouse
allograft models (15). To the best of our knowledge, there
are no previous reports of itraconazole use in HO (26), but
being itraconazole a drug frequently used in immunosuppressed
children, it was ruled into the protocol. Disappointingly, after
four months on itraconazole, the patient presented the formation
of two new plates and the progression of older ones, and the drug
was discontinued.
Corticosteroids are drugs with immunomodulatory and anti-
inflammatory potential. Dosages of 2 mg/kg/once daily for
four days are indicated for FOP as first-line treatment at the
beginning of the flare-ups (26, 36). It is reported that up to
55% of subjects suffering from FOP experiment have some kind
of symptom improvement after its use, but current protocols
advise against its long-term use and restrict this treatment
option to flare-ups impairing mobility of major joints, to
primary prevention after severe trauma or whenever undergoing
a surgery (26). We infused a high dose of corticosteroid
(20 mg/kg of daily intravenous methylprednisolone, for five
days) followed by a slow six-month tapering period. Although
chemical parameters of bone formation dropped, laboratory
findings were not accompanied by any modification of visible
ectopic bone formation. A course of oral corticosteroids was
previously offered by Morales et al. (16) to their patient to
no benefit.
Non-steroidal anti-inflammatory drugs (NSAIDs) like
indomethacin are supposed to inhibit prostaglandin production,
avoiding mesenchymal cell differentiation. Its use in the
prevention of HO after hip arthroplasty (17) and spinal
cord injury (SCI) (32) is well-established. On the other
hand, evidence for this therapeutic approach for flare-up
prevention in FOP is lacking (26). Indomethacin has been
previously tried on another POH patient (18), but it did
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FIGURE 2 | Tridimensional TC of the pelvis and lower limbs, showing the evolution of ectopic calcification in the right leg, as well as the progression of ankylosis,
asymmetry, and tibial combing of the left leg.
not stop worsening. Despite receiving indomethacin for
the last 14 months, our patient presented two flare-up
periods and recurrence of the bony plate under the surgical
incision (Figure 2 and Supplementary Figure 4). Also, we
lack data on PINP and beta-crosslaps during indomethacin
administration, as regular blood tests were discontinued to avoid
further visits.
Our report is not the first one communicating the
astonishingly different clinical expression of the disease in
two siblings (37) nor within one family (38), but to the best
of our knowledge is the only one with POH affecting two
identical twins carrying the same mutation at the GNAS
gene. It was known that a specific mutation pattern within
GNAS could not predict the severity nor progression of the
disease (39–41), but until today, we have no evidence that two
patients with identical genetic backgrounds could have such a
different evolution.
Laboratory tests are therefore of limited utility in POH
patients (16, 42–49). Markers that show an increased bone
turnover have been reported by Seror et al. (30) andHou (31).We
found a huge unbalance between PINP and beta-crosslaps, but
we could not correlate their values with disease activity. Through
most of follow-up, levels of PINP were constantly elevated,
save for the periods following administration of pamidronate
and methylprednisolone. Although a blatant decrease of both
parameters was seen after bisphosphonate infusion, and that
drop of PINP was accompanied by a rise in bone resorption
when pulses of methylprednisolone were given, in no case that
change in concentration of biochemical markers was followed by
a relapse of the disease. It is also worth noting that IGF-1 remains
low two years after discontinuation of its ectopic administration
(63 ng/ml, normal range 80–233 ng/ml).
Hypermetabolism, ankylosis of left leg, and retraction in right
inferior member have taken their toll on Patient 1, who is
progressively separating from her height and weight percentiles.
Lesions can recur after surgical removal (16, 18, 43, 50), as
happened to our patient. So far, none of our therapeutic
approaches worked. This may be due to insufficient dosage, but
the most likely reason is that the nature of POH ossification is
different from that induced by FOP and HO, together with our
unknowledge of the pathological model that drives ectopic bone
formation in POH. There have been reports of other potential
treatments, like radiation therapy (14, 51) and Imatinib (26, 52–
54), but the effects of their use in children with disseminated
ectopic bone formation would be deleterious. Using a control
group for POH patients is utopic, even for our case, who had
his genetic identical twin developing a total distinct phenotype
but remains largely unaffected. To date, diligent skin care and
physical therapies are the only recommendations we can make
(47), and sharing our experience on this blatantly ignored entity
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may help others to overcome the lack of information on in
vivo results.
CONCLUSIONS
We presented a unique case of POH in two genetically
identical patients with totally discordant clinical courses. They
confirm that another unknown molecular mechanism beyond a
GNAS mutation should be accountable for this wide phenotype
variation. We failed at finding any medication that could
ameliorate the symptoms of POH.
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Supplementary Figure 1 | This AP radiographs the evident web-like pattern of
the POH. This reflects the clinical situation of the patient before starting the
different treatments. Note the affected growth of the left leg, ankylosis of left knee
and ankle, luxation of several joints of the left lower limb and foot (knee, ankle,
tarso-metatarsal, etc.), and combing, resorption, remodeling, and cortical fractures
of large bones. Also, a bony plate is visible in the dermis over the right knee.
Although palpable, at that time, it did not greatly impaired mobility of this joint.
Supplementary Figure 2 | Heatmap of identity-by-descent (IBD) values
represented as p(IBD = 2) + 0.5 × p(IBD = 1) obtained from pairwise genome
profile comparisons of the samples collected from the patients (coded as P1 and
P2 in the figure). The data indicate that both sisters are genetically identical and do
not show detectable mosaicism in the samples analyzed. IBD values for all pairs of
genetic profiles are compatible with a twin relationship or samples coming from
the same biological source (55); according to the Lee test (56), this relationship is
highly statistically significant (p-value < 10−16 in all pairwise comparisons). We
used the Applied BiosystemsTM AxiomTM Spain Biobank Array to genotype blood
and saliva samples from Patient 1 and Patient 2, and a bone plate sample from
the severely affected Patient 1. IBD values for all pairwise comparisons were
obtained for a total of 715,195 SNPs. To infer kinship relations based on the
genome evidence, we followed the procedures previously described in (57, 58).
We used 10 random Spanish genome profiles obtained from The 1,000 Genomes
Project (IBS-1000G) (indicated with prefix “HG” in the figure) as reference samples
for IBD computation.
Supplementary Figure 3 | Original flowchart of therapeutic options after IGF-1
administration for Patient 1. rhIGF-1 was the first treatment provided due to the
persistent low levels detected since her birth. NSAIDs were provided for
symptomatic relief whenever necessary. Our protocol also involved the extraction
of blood samples previous to, during, and after stopping treatment, and,
whenever a plate required removal, the storage of both calcified and surrounding
mesenchymal tissue for in vitro treatment testing.
Supplementary Figure 4 | Taken before starting corticoid therapy. It shows the
progression of heterotopic bone formation in the right lower limb, especially over
the medial surface of the tibia. Calcification has affected also part of the right ankle
and the dermis over the adductors. The asymmetry between both lower limbs is
evident (it has progressed since the initial radiograph), as well as ankylosis of both
left knee and ankle. The surgical incision is the result of the removal of a bony
abdominal plate that caused pain when sitting, which coupled with the
impossibility of prolonged standing due to evident motives and impacted heavily
on the quality of life. Shortly after taking this image, the patient underwent an
orthopedic surgery for liberating the right knee, whose movements were also
limited. The right leg was the one allowing walking in the patient after total
ankylosis of the left leg.
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